Literature DB >> 8857596

Chronic intrathecal morphine treatment does not cause down-regulation of spinal adenosine A1 receptors in rats.

P L Tao1, C S Wong, M C Lin.   

Abstract

We have shown previously that systemic chronic morphine treatment causes down-regulation of spinal adenosine A1 receptors in rats. Recently, we have found that chronic supraspinal morphine treatment also causes this effect. In the present study, we investigated whether chronic spinal morphine treatment has the same effect of down-regulation of spinal adenosine A1 receptors. Adult male Sprague-Dawley rats were rendered tolerant to morphine either by multiple intrathecal (i.t.) injections or continuous i.t. infusion by osmotic pump administration for 2 or 4 days. Spinal A1-adenosine receptor binding activity was measured by using the selective A1 adenosine agonist [3H]cyclohexyladenosine. No significant decrease in [3H]cyclohexyladenosine binding was found in the spinal cord after 2 or 4 days of multiple i.t. injections of morphine. There was also no significant change in the amount of spinal [3H]cyclohexyladenosine bound after 4 days of continuous i.t. infusion of morphine by osmotic pump. From these and our previous results, it is concluded that only supraspinal chronic morphine treatment down regulates the spinal A1 adenosine receptor and this may play a role in the mechanism of supraspinal morphine tolerance but not spinal morphine tolerance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8857596     DOI: 10.1007/bf00178719

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  30 in total

1.  Involvement of adenosine in the spinal antinociceptive effects of morphine and noradrenaline.

Authors:  M I Sweeney; T D White; J Sawynok
Journal:  J Pharmacol Exp Ther       Date:  1987-11       Impact factor: 4.030

2.  Intracerebroventricular morphine releases adenosine and adenosine 3',5'-cyclic monophosphate from the spinal cord via a serotonergic mechanism.

Authors:  M I Sweeney; T D White; J Sawynok
Journal:  J Pharmacol Exp Ther       Date:  1991-12       Impact factor: 4.030

3.  Spinal adenosine modulates descending antinociceptive pathways stimulated by morphine.

Authors:  G E DeLander; C J Hopkins
Journal:  J Pharmacol Exp Ther       Date:  1986-10       Impact factor: 4.030

4.  Morphine-induced downregulation of mu-opioid receptors in neonatal rat brain.

Authors:  A Tempel; J Habas; W Paredes; G A Barr
Journal:  Brain Res       Date:  1988-06-01       Impact factor: 3.252

5.  The antinociceptive effect of intrathecally administered adenosine analogs in mice correlates with the affinity for the A1-adenosine receptor.

Authors:  R Karlsten; C Post; I Hide; J W Daly
Journal:  Neurosci Lett       Date:  1991-01-02       Impact factor: 3.046

6.  Selective changes in mu opioid receptor properties induced by chronic morphine exposure.

Authors:  L L Werling; P N McMahon; B M Cox
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

7.  Spinal antinociception by adenosine analogs and morphine after intrathecal administration of the neurotoxins capsaicin, 6-hydroxydopamine and 5,7-dihydroxytryptamine.

Authors:  J Sawynok; A Reid; D Nance
Journal:  J Pharmacol Exp Ther       Date:  1991-07-01       Impact factor: 4.030

8.  Autoradiographic evidence for decrease in binding of mu- and delta-opioid receptors after subchronic [D-Ala2,D-Leu5]enkephalin treatment in rats.

Authors:  P L Tao; V S Seybold; H H Loh
Journal:  Eur J Pharmacol       Date:  1993-02-09       Impact factor: 4.432

9.  Morphine activates omega-conotoxin-sensitive Ca2+ channels to release adenosine from spinal cord synaptosomes.

Authors:  C M Cahill; T D White; J Sawynok
Journal:  J Neurochem       Date:  1993-03       Impact factor: 5.372

10.  Morphine (intracerebroventricular) activates spinal systems to inhibit behavior induced by putative pain neurotransmitters.

Authors:  G E DeLander; J J Wahl
Journal:  J Pharmacol Exp Ther       Date:  1989-12       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.